Apogee Therapeutics Ownership | Who Owns Apogee Therapeutics?
Apogee Therapeutics Ownership Summary
Apogee Therapeutics is owned by 98.96% institutional investors, 7.60% insiders. Vr adviser is the largest institutional shareholder, holding 14.54% of APGE shares.
APGE Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | Apogee Therapeutics | 98.96% | 7.60% | -6.56% |
| Sector | Healthcare Stocks | 488.17% | 11.08% | -399.26% |
| Industry | Biotech Stocks | 306.59% | 11.10% | -217.69% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Vr adviser | 8.49M | 14.54% | $368.86M |
| Rtw investments, lp | 2.71M | 4.64% | $117.79M |
| Blackrock funding, inc. /de | 2.56M | 4.39% | $111.29M |
| Driehaus capital management | 2.31M | 3.95% | $100.36M |
| Fairmount funds management | 2.05M | 3.51% | $88.97M |
| Braidwell lp | 1.48M | 2.53% | $64.21M |
| Adage capital partners gp | 1.29M | 2.21% | $56.04M |
| Point72 asset management | 1.23M | 2.11% | $53.44M |
| Perceptive advisors | 1.18M | 2.02% | $51.34M |
| Mercer global advisors inc /adv | 820.38K | 1.40% | $35.63M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Vr adviser | 8.49M | 27.64% | $368.86M |
| Fairmount funds management | 2.05M | 11.53% | $88.97M |
| Affinity asset advisors | 691.90K | 4.10% | $30.05M |
| Allostery investments lp | 6.00K | 3.32% | $260.58K |
| Braidwell lp | 1.48M | 2.20% | $64.21M |
| Ikarian capital | 232.05K | 1.94% | $10.08M |
| Perceptive advisors | 1.18M | 1.90% | $51.34M |
| Rtw investments, lp | 2.71M | 1.68% | $117.79M |
| Novo | 449.39K | 1.38% | $19.52M |
| Siren | 594.99K | 1.34% | $25.84M |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Point72 asset management | 1.23M | 0.10% | 837.89K |
| Adage capital partners gp | 1.29M | 0.09% | 563.46K |
| Novo | 449.39K | 1.38% | 449.39K |
| Ikarian capital | 232.05K | 1.94% | 232.05K |
| Jefferies financial group | 642.36K | 0.23% | 220.56K |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Octagon capital advisors lp | - | - | -10.70M |
| Ra capital management | - | - | -1.57M |
| Mercer global advisors inc /adv | 820.38K | 0.07% | -819.80K |
| Affinity asset advisors | 691.90K | 4.10% | -459.30K |
| Blackrock funding, inc. /de | 2.56M | 0.00% | -348.29K |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Novo | 449.39K | 1.38% | 449.39K | $19.52M |
| Ikarian capital | 232.05K | 1.94% | 232.05K | $10.08M |
| Boothbay fund management | 85.18K | 0.07% | 85.18K | $3.70M |
| Stempoint capital lp | 84.47K | 1.18% | 84.47K | $3.67M |
| Weiss asset management lp | 82.30K | 0.04% | 82.30K | $3.57M |
Sold Out
| Holder | Change |
|---|---|
| True wealth design | -1.00 |
| Southstate | -5.00 |
| Quantbot technologies lp | -5.00 |
| Parallel advisors | -6.00 |
| Stephens consulting | -10.00 |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 30, 2025 | 194 | 9.60% | 57,823,236 | -17.56% | 98 | 0.68% | 93 | 9.41% | 64 | 8.47% |
| Mar 31, 2025 | 178 | 11.25% | 72,188,053 | 28.01% | 124 | 1.19% | 85 | -10.53% | 59 | 55.26% |
| Dec 31, 2024 | 162 | 10.96% | 57,868,275 | 3.16% | 104 | 1.07% | 97 | 29.33% | 38 | -17.39% |
| Sep 30, 2024 | 146 | 4.29% | 56,094,430 | 3.58% | 98 | 1.08% | 75 | -7.41% | 46 | 12.20% |
| Jun 30, 2024 | 140 | - | 54,153,585 | 2.36% | 95 | 0.86% | 81 | -28.32% | 41 | 115.79% |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Sep 03, 2025 | Dambkowski Carl | Chief Medical Officer | Sell | $95.87K |
| Sep 03, 2025 | Dambkowski Carl | Chief Medical Officer | Sell | $7.32K |
| Aug 06, 2025 | Dambkowski Carl | Chief Medical Officer | Sell | $102.95K |
| Jul 02, 2025 | Dambkowski Carl | Chief Medical Officer | Sell | $133.51K |
| Jul 02, 2025 | Dambkowski Carl | Chief Medical Officer | Sell | $34.51K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2025 Q3 | - | 6 |
| 2025 Q2 | - | 5 |
| 2025 Q1 | - | 10 |
| 2024 Q4 | 2 | 13 |
| 2024 Q3 | - | 11 |
APGE Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools